{
  "pmcid": "9748994",
  "sha256": "1f22717d1bae3d87713a957ab0c4a607387d27108c27539236a40dcb7ea7c039",
  "timestamp_utc": "2025-11-09T23:01:56.966546+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.690878721859114,
    "reading_ease": 36.704248366013104,
    "word_count": 243
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Tranexamic Acid in Postpartum Haemorrhage"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "In this double-blind, placebo-controlled, randomised trial, women experiencing PPH during Caesarean delivery were randomised to receive placebo (n=57), TXA 0.5 g (n=51), or TXA 1 g (n=53) across eight centres in France from March 2016 to December 2019."
      },
      "Participants": {
        "score": 2,
        "evidence": "women experiencing PPH during Caesarean delivery were randomised"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised to receive placebo (n=57), TXA 0.5 g (n=51), or TXA 1 g (n=53)"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to determine the doseâ€“effect relationship for two regimens of intravenous TXA versus placebo."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the difference in the increase over baseline in plasma D-dimer level 120 min after infusion."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed."
      },
      "Blinding": {
        "score": 3,
        "evidence": "Blinding included patients, clinicians, and outcome assessors."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "randomised to receive placebo (n=57), TXA 0.5 g (n=51), or TXA 1 g (n=53) across eight centres in France from March 2016 to December 2019."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "In the placebo group, hyperfibrinolysis was evidenced by a mean increase over baseline of 93% for D-dimer level at 120 min."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "A dose of TXA 1 g was associated with smaller increases over baseline (D-dimers: 38%, p=0.003 vs placebo)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were more frequent in the 1 g group but not severe."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT 02797119."
      },
      "Funding": {
        "score": 1,
        "evidence": "The study was funded by independent agencies with no influence on the study design or reporting."
      }
    },
    "total_score": 24,
    "max_score": 25
  }
}